Evidence map›Paper›PMID 36077436›Full record

ArticleInternational journal of molecular sciences2022

Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients.

Ottavia Giampaoli, Fabio Sciubba, Elisa Biliotti, Mariangela Spagnoli, Riccardo Calvani, Alberta Tomassini, Giorgio Capuani, Alfredo Miccheli, Gloria Taliani

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Metabolomics in viral hepatitis: advances and review.Frontiers in cellular and infection microbiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ottavia GiampaoliNMR-Based Metabolomics Laboratory (NMLab), Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-1336-3102
Fabio SciubbaNMR-Based Metabolomics Laboratory (NMLab), Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-1982-2712
Elisa BiliottiDepartment of Clinical Medicine, Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
Mariangela SpagnoliDepartment of Occupational Medicine, Epidemiology and Hygiene, INAIL, Monte Porzio Catone, 00078 Rome, Italy.ORCID 0000-0001-9061-7159
Riccardo CalvaniFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.ORCID 0000-0001-5472-2365
Alberta TomassiniNMR-Based Metabolomics Laboratory (NMLab), Sapienza University of Rome, 00185 Rome, Italy.
Giorgio CapuaniNMR-Based Metabolomics Laboratory (NMLab), Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-6992-2578
Alfredo MiccheliNMR-Based Metabolomics Laboratory (NMLab), Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-1487-4043
Gloria TalianiDepartment of Clinical Medicine, Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0001-8077-4580
Sapienza University of Rome · ITPoliclinico Umberto I · ITAgostino Gemelli University Polyclinic · ITIstituto Nazionale per l'Assicurazione Contro gli Infortuni sul Lavoro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most commonly used antiviral treatment against hepatitis C virus is a combination of direct-acting antivirals (DAAs) and ribavirin (RBV), which leads to a shortened duration of therapy and a sustained virologic response until 98%. Nonetheless, several dose-related side effects of RBV could limit its applications. This study aims to measure the urinary concentration of RBV and its main metabolites in order to evaluate the drug metabolism ability of HCV patients and to evaluate the adverse effects, such as anemia, with respect to RBV metabolite levels. RBV and its proactive and inactive metabolites were identified and quantified in the urine of 17 HCV males with severe liver fibrosis using proton nuclear magnetic resonance (

Indexed as

Hepatitis CHepatitis C, ChronicAntiviral AgentsDrug Therapy, CombinationHepacivirusHumansMalePrecision MedicineRecombinant ProteinsRibavirinTreatment OutcomeAntiviral AgentsRecombinant ProteinsRibavirin1H-NMRhepatitis C virus (HCV)ribavirin (RBV)severe liver fibrosisurinary metabolites

Identifiers

PMID36077436
PMCPMC9456413
OpenAlexW4294314591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.